The similarity between the effects of RXP470.1 and MMP-12 gene deletion in models of atherosclerosis and viral infection3, 5 suggests that MMP-12 active form is the privileged target for this inhibitor in vivo. This evidence concerns the gene MMP12 and atherosclerosis.